About mereo biopharma group plc - MREO
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
MREO At a Glance
Mereo BioPharma Group Plc
1 Cavendish Place
London, Greater London W1G 0QF
| Phone | 44-333-023-7300 | Revenue | 501.17K | |
| Industry | Biotechnology | Net Income | -41,975,863.47 | |
| Sector | Health Technology | Employees | 39 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MREO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 132.554 |
| Price to Book Ratio | 1.621 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.652 |
| Enterprise Value to Sales | 51.164 |
| Total Debt to Enterprise Value | 0.008 |
MREO Efficiency
| Revenue/Employee | 12,850.473 |
| Income Per Employee | -1,076,304.192 |
| Receivables Turnover | 0.253 |
| Total Asset Turnover | 0.008 |
MREO Liquidity
| Current Ratio | 10.465 |
| Quick Ratio | 10.465 |
| Cash Ratio | 9.529 |
MREO Profitability
| Gross Margin | -156.40 |
| Operating Margin | -8,081.401 |
| Pretax Margin | -8,745.60 |
| Net Margin | -8,375.60 |
| Return on Assets | -68.64 |
| Return on Equity | -82.399 |
| Return on Total Capital | -102.086 |
| Return on Invested Capital | -82.248 |
MREO Capital Structure
| Total Debt to Total Equity | 0.494 |
| Total Debt to Total Capital | 0.491 |
| Total Debt to Total Assets | 0.44 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |